Zhimeng Biopharma Closes $35 Million Funding for Trials of HBV Therapy

Shanghai Zhimeng Biopharma closed a $35 million Series A round to support clinical trials of its novel hepatitis B virus nucleocapsid inhibitor and other products. Zhimeng started a US-based Phase I dose escalation study of ZM-H1505R, its lead HBV therapy, earlier this year. Zhimeng develops treatments for chronic hepatitis B infection and CNS therapies for stroke, epilepsy and other neurological disorders. The A round was led by Trinity Innovation Fund and included SDIC, Oceanpine Healthcare Fund and Photon Fund. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.